# The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

> **NCT01002872** · NA · COMPLETED · sponsor: **Endeavor Health** · enrollment: 19 (actual)

## Conditions studied

- Metabolic Bone Disease

## Interventions

- **DRUG:** Lanthanum Carbonate (Fosrenol)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01002872
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002872, "The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01002872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*